 |
Immune globulin intravenous, human |
|---|---|
| Trade Name | Gamimune N |
| Orphan Indication | Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus |
| USA Market Approval | USA |
| USA Designation Date | 1993-02-18 00:00:00 |
| Sponsor | Bayer Corporation;Pharmaceutical Division, Biological Products, 400 Morgan Lane;New Haven, Connecticut, 06516 |
